Trial Profile
A Trail of Neoadjuvant Endostar in Combination With Docetaxel, Epirubicin and Cyclophosphamide in Patients With Stage III Breast Cancer (TENDENCY)
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 06 Dec 2021
Price :
$35
*
At a glance
- Drugs Endostatin (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin
- Indications Advanced breast cancer; Early breast cancer
- Focus Therapeutic Use
- Acronyms TENDENCY
- 07 Aug 2019 Planned initiation date (Estimated Study Start Date) changed from 1 Aug 2018 to 1 Aug 2019.
- 07 Aug 2019 Status changed from not yet recruiting to recruiting.
- 29 Aug 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2021.